Search results for "Covid."

showing 10 items of 2543 documents

Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19☆

2020

Pneumonia caused by coronavirus, which originated in Wuhan, China, in late 2019, has been spread around the world already becoming a pandemic. Unfortunately, there is not yet a specific vaccine or effective antiviral drug for treating COVID-19. Many of these patients deteriorate rapidly and require intubation and are mechanically ventilated, which is causing the collapse of the health system in many countries due to lack of ventilators and intensive care beds. In this document we review two simple adjuvant therapies to administer, without side effects, and low cost that could be useful for the treatment of acute severe coronavirus infection associated with acute respiratory syndrome (SARS-C…

0301 basic medicinemedicine.medical_specialtyVitamina Cmedicine.drug_classLung injurymedicine.disease_causeArticle03 medical and health sciences0302 clinical medicineOzoneIntensive caremedicineAdjuvant therapyVitamin CIntensive care medicineOzonoCoronavirusbusiness.industrySARS-CoV-2COVID-19030208 emergency & critical care medicineGeneral MedicineAscorbic acidmedicine.diseaseClinical trialPneumonia030104 developmental biologyAntiviral drugbusinessRevista Española de Anestesiología y Reanimación (English Edition)
researchProduct

Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors. Prospective analysis from a multicentre observational tri…

2020

Background:This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020. The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020. All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, the study prospectively recorded all the COVID-19 ILI events.Patients and methods:Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared …

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatmentimmune-checkpoint inhibitorsinfluenza-like illnesslcsh:RC254-28203 medical and health sciences0302 clinical medicineCancer immunotherapyInternal medicineMedicineProspective cohort studyCancer stagingOriginal ResearchInfluenza-like illnessbusiness.industrySARS-CoV-2virus diseasesCOVID-19Immunotherapycancer patients; COVID-19; immune-checkpoint inhibitors; influenza-like illness; SARS-CoV-2lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseComorbidityVaccination030104 developmental biologyOncology030220 oncology & carcinogenesisObservational studybusinesscancer patients
researchProduct

Does Evidence Exist to Blunt Inflammatory Response by Nutraceutical Supplementation during COVID-19 Pandemic? An Overview of Systematic Reviews of Vi…

2021

More than one year has passed since the first cases of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome (SARS)-CoV-2 coronavirus were reported in Wuhan (China), rapidly evolving into a global pandemic. This infectious disease has become a major public health challenge in the world. Unfortunately, to date, no specific antivirals have been proven to be effective against COVID-19, and although a few vaccines are available, the mortality rate is not decreasing but is still increasing. One therapeutic strategy has been focused on infection prevention and control measures. In this regard, the use of nutraceutical supports may play a role against some aspect of the i…

0301 basic medicinemedicine.medical_specialtyoverviewvitamin Clcsh:TX341-641vitamin DmelatoninAscorbic AcidCochrane LibraryMelatonin03 medical and health sciences0302 clinical medicineNutraceuticalImmune systemMeta-Analysis as Topicsystematic reviewInternal medicineVitamin D and neurologyMedicineInfection controlHumans030212 general & internal medicinenutraceuticalsNutrition and DieteticsVitamin Cbusiness.industrySARS-CoV-2zincCOVID-19VitaminsTrace ElementsCOVID-19 Drug Treatment030104 developmental biologySystematic reviewC-Reactive ProteininflammationImmune SystemDietary Supplementsbusinesslcsh:Nutrition. Foods and food supplyFood Sciencemedicine.drug
researchProduct

Are There Any Parameters Missing in the Mathematical Models Applied in the Process of Spreading COVID-19?

2021

Simple Summary Nowadays, enhancing development of mathematical models is very important to help in the prediction of coronavirus disease 2019 (COVID1-19). However, the vast majority of published model-based predictions do not cover people who left the epidemic COVID-19 positive (alive) and they must be included in studies to guarantee a more accurate model for application in public health. The epidemic development phenomenon can be obtained with a modelling framework. Abstract On 11 March 2020, coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization (WHO). As of 12.44 GMT on 15 January 2021, it has produced 93,640,296 cases and 2,004,984 deaths. The use …

0301 basic medicinemodelling studyProcess (engineering)media_common.quotation_subjectControl (management)Social WelfareBiologia Models matemàticsBiologyArticleGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicinePhenomenonPandemicUK030212 general & internal medicineDuration (project management)Epidemiologialcsh:QH301-705.5media_commonActuarial scienceGeneral Immunology and MicrobiologyMathematical modelCOVID-19Virus030104 developmental biologylcsh:Biology (General)ItalySpainGeneral Agricultural and Biological SciencesSeriousnessBiology
researchProduct

COVID-19 Sepsis and Microcirculation Dysfunction

2020

The spreading of Coronavirus (SARS-CoV-2) pandemic, known as COVID-19, has caused a great number of fatalities all around the World. Up to date (2020 May 6) in Italy we had more than 28,000 deaths, while there were more than 205.000 infected. The majority of patients affected by COVID-19 complained only slight symptoms: fatigue, myalgia or cough, but more than 15% of Chinese patients progressed into severe complications, with acute respiratory distress syndrome (ARDS), needing intensive treatment. We tried to summarize data reported in the last months from several Countries, highlighting that COVID-19 was characterized by cytokine storm (CS) and endothelial dysfunction in severely ill patie…

0301 basic medicinemyalgiamedicine.medical_specialtyARDSPhysiologyMini ReviewmicrocirculationDiseaseangiotensin II030204 cardiovascular system & hematologylcsh:PhysiologyMicrocirculationSepsis03 medical and health sciences0302 clinical medicinePhysiology (medical)medicineEndothelial dysfunctionIntensive care medicinethromboxane (TxB2)lcsh:QP1-981business.industryangiotensin II; COVID-19; endothelial cells; microcirculation; thromboxane (TxB2)COVID-19medicine.diseaseAngiotensin IIendothelial cells030104 developmental biologymedicine.symptomCytokine stormbusinessFrontiers in Physiology
researchProduct

Application of a portable instrument for rapid and reliable detection of SARS-CoV-2 infection in any environment

2020

Abstract The ongoing outbreak of the novel coronavirus (SARS‐CoV‐2) infection is creating serious challenges for health laboratories that seek to identify viral infections as early as possible, optimally at the earliest appearance of symptom. Indeed, there is urgent need to develop and deploy robust diagnostic methodologies not only to use in health laboratory environments but also directly in places where humans circulate and spread the virus such as airports, trains, boats, and any public aggregation places. The success of a reliable and sensitive asymptomatic diagnosis relies on the identification and measurement of informative biomarkers from human host and virus in a rapid, sensitive, …

0301 basic medicineportableSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralImmunologycoronavirusBiologymedicine.disease_causeSensitivity and SpecificityDisease OutbreaksWorkflowBetacoronavirus03 medical and health sciencesCOVID-19 Testing0302 clinical medicinePandemicmedicineAnimalsHumansMass ScreeninginstrumentImmunology and AllergyBiomarker discoveryAsymptomatic InfectionsPandemicsdeviceMass screeningCoronavirusInvited ReviewClinical Laboratory TechniquesSARS-CoV-2COVID-19Reproducibility of ResultsClinical Laboratory Servicescoronavirus; device; instrument; portable; SARS-CoV-2 detection; Animals; Asymptomatic Infections; Betacoronavirus; Biomarkers; Clinical Laboratory Services; Clinical Laboratory Techniques; Coronavirus Infections; Disease Outbreaks; Humans; Mass Screening; Pandemics; Pneumonia Viral; Reproducibility of Results; Sensitivity and Specificity; WorkflowIdentification (information)030104 developmental biologyWorkflowRisk analysis (engineering)SARS‐CoV‐2 detectionCoronavirus InfectionsHost (network)Biomarkers030215 immunology
researchProduct

Do genetic polymorphisms in angiotensin converting enzyme 2 (ACE2) gene play a role in coronavirus disease 2019 (COVID-19)?

2020

Abstract Although some demographic, clinical and environmental factors have been associated with a higher risk of developing coronavirus disease 2019 (COVID-19) and progressing towards severe disease, altogether these variables do not completely account for the different clinical presentations observed in patients with comparable baseline risk, whereby some subjects may remain totally asymptomatic, whilst others develop a very aggressive illness. Some predisposing genetic backgrounds can hence potentially explain the broad inter-individual variation of disease susceptibility and/or severity. It has been now clearly established that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2…

0301 basic medicinereceptorClinical BiochemistryPopulationPneumonia ViralAdipose tissueInflammationPeptidyl-Dipeptidase AAsymptomaticViruspolymorphism03 medical and health sciencesBetacoronavirus0302 clinical medicineProtein DomainsFibrosismedicineHumans030212 general & internal medicineeducationGenePandemicseducation.field_of_studyPolymorphism Geneticbusiness.industrySARS-CoV-2Biochemistry (medical)COVID-19General Medicineangiotensinmedicine.diseaseenzyme030104 developmental biologyCOVID-19 angiotensin enzyme polymorphism receptorImmunologyAngiotensin-converting enzyme 2Spike Glycoprotein CoronavirusReceptors VirusAngiotensin-Converting Enzyme 2medicine.symptombusinessCoronavirus InfectionsProtein Binding
researchProduct

PNPLA3 and TLL-1 Polymorphisms as Potential Predictors of Disease Severity in Patients With COVID-19

2021

Albeit the pathogenesis of COVID-19 remains unclear, host’s genetic polymorphisms in genes involved in infection and reinfection, inflammation, or immune stimulation could play a role in determining the course and outcome. We studied in the early phase of pandemic consecutive patients (N = 383) with SARS-CoV-2 infection, whose subsequent clinical course was classified as mild or severe, the latter being characterized by admission to intensive therapy unit or death. Five host gene polymorphisms (MERTK rs4374383, PNPLA3 rs738409, TLL-1 rs17047200, IFNL3 rs1297860, and INFL4 rs368234815) were assessed by using whole nucleic acids extracted from nasopharyngeal swabs. Specific protease cleavage …

0301 basic medicineseverity of diseaseQH301-705.5InflammationPathogenesisCell and Developmental Biology03 medical and health sciences0302 clinical medicineDownregulation and upregulationGenotypemedicinegenetic polymorphismBiology (General)GeneOriginal Researchbusiness.industryConfoundingCOVID-19InflammasomeCell BiologyMERTK030104 developmental biology030220 oncology & carcinogenesisImmunologymedicine.symptombusinessPNPLA3 I148MTLL-1Developmental Biologymedicine.drugFrontiers in Cell and Developmental Biology
researchProduct

Statistical Explorations and Univariate Timeseries Analysis on COVID-19 Datasets to Understand the Trend of Disease Spreading and Death

2020

&ldquo

0301 basic medicinetransmission ratepopulationSevere Acute Respiratory Syndromemedicine.disease_causelcsh:Chemical technologyBiochemistryRNNDisease OutbreaksAnalytical Chemistry0302 clinical medicinePandemiclcsh:TP1-1185030212 general & internal medicineInstrumentationVDP::Teknologi: 500::Informasjons- og kommunikasjonsteknologi: 550Coronaviruskeraseducation.field_of_studypublic healthartificial intelligenceAtomic and Molecular Physics and OpticsRegressionmachine learningGeographySevere acute respiratory syndrome-related coronavirusstatisticsMiddle East Respiratory Syndrome Coronaviruscommunity diseaseregressionCoronavirus InfectionsLSTMPneumonia ViralPopulationWorld Health OrganizationArticleBetacoronavirusspread factor03 medical and health sciencesCode (cryptography)medicineAnimalsHumansElectrical and Electronic EngineeringeducationPandemicsmeasurable sensor dataalgorithmSARS-CoV-2ICDUnivariatedeep learningOutbreakCOVID-19medicine.diseasehypothesis testpython030104 developmental biologycorrelationCatsMiddle East respiratory syndromeCattleDemographySensors
researchProduct

Guidelines Have a Key Role in Driving HCV Elimination by Advocating for Simple HCV Care Pathways.

2021

The availability of pangenotypic direct-acting antivirals for treatment of hepatitis C (HCV) has provided an opportunity to simplify patient pathways. Recent clinical practice guidelines have recognised the need for simplification to ensure that elimination of HCV as a public health concern remains a priority. Despite the move towards simplified treatment algorithms, there remains some complexity in the recommendations for the management of genotype 3 patients with compensated cirrhosis. In an era where additional clinical trial data are not anticipated, clinical guidance should consider experience gained in real-world settings. Although more experience is required for some pangenotypic the…

030213 general clinical medicinemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)EliminationGuidelineGuidelinesGlobal HealthAntiviral AgentsPatient pathwaySimplification03 medical and health sciences0302 clinical medicinePandemicGlobal healthMedicineHumansPharmacology (medical)Disease EradicationIntensive care medicineAntiviral Agentbusiness.industrySARS-CoV-2Public healthCOVID-19General MedicineHepatitis CHcv eliminationClinical trialCritical Pathway030220 oncology & carcinogenesisCommunicable Disease ControlPractice Guidelines as TopicKey (cryptography)Critical PathwaysCommentarybusinessHumanAdvances in therapy
researchProduct